National Health (Originator Brand) Amendment Determination (April Update) 2026

Overview

The National Health (Originator Brand) Amendment Determination (April Update) 2026 amends the National Health (Originator Brand) Determination 2025 under subsection 99ADB(6B) of the National Health Act 1953. This legislative instrument is necessary to implement the removal of originator brand data from price disclosure calculations in certain circumstances, as outlined in the National Health (Pharmaceutical Benefits) Regulations 2017. The determination of originator brands for pharmaceutical items affects the pricing of medications on the Pharmaceutical Benefits Scheme (PBS) F2 formulary, potentially increasing price reductions for consumers. The Pharmaceutical Benefits Scheme operates under Part VII of the National Health Act 1953, regulating the listing, prescribing, pricing, charging, and payment of subsidies for drugs and medicinal preparations. The instrument aims to ensure that price disclosure more accurately reflects the market prices of generic brands, thereby improving the affordability and accessibility of medications for Australians. The legislative instrument is compatible with human rights as it aids in the progressive realisation of the right to the highest attainable standard of physical and mental health, as recognised in Articles 2 and 12 of the International Covenant on Economic, Social and Cultural Rights. By facilitating better value for money through price disclosure reductions, this amendment supports the PBS's mission to provide timely, reliable, and affordable access to necessary and cost-effective medicines. The amendment assists consumers by potentially reducing out-of-pocket costs for some PBS medicines, thereby contributing positively to the health and wellbeing of Australians.

Scope and Application

The National Health (Originator Brand) Amendment Determination (April Update) 2026 amends the National Health (Originator Brand) Determination 2025 to address the originator brand status for four specific drugs that will be included in the Pharmaceutical Benefits Scheme (PBS) F2 formulary on 1 April 2026. This instrument is crucial for implementing the removal of originator brand data from price disclosure calculations under the National Health (Pharmaceutical Benefits) Regulations 2017, which is expected to lead to increased price reductions on the PBS by ensuring that government prices more accurately reflect the prices of generic brands. This amendment applies to the pharmaceutical items of the drugs beclometasone with formoterol, desmopressin, progesterone, and safinamide, all of which are moving from the F1 formulary or the Combination Drug List (CDL) to F2. The Pharmaceutical Benefits Scheme operates under the National Health Act 1953, regulating various aspects of drug provision, including listing, prescribing, pricing, and subsidy payments. The amendment takes effect on 1 April 2026 and is made under the authority of the National Health Act 1953, specifically section 99ADB(6B). This legislative instrument is compatible with human rights, as it supports the progressive realisation of the right to the highest attainable standard of physical and mental health by facilitating more affordable access to essential medications through the PBS.

Key Provisions

The National Health (Originator Brand) Amendment Determination (April Update) 2026 (PB 41 of 2026) amends the National Health (Originator Brand) Determination 2025 (PB 114 of 2025) to determine originator brand status for four pharmaceutical items that are moving from the F1 formulary or the Combination Drug List (CDL) to the F2 formulary of the Pharmaceutical Benefits Scheme (PBS) on 1 April 2026. These drugs are beclometasone with formoterol, desmopressin, progesterone, and safinamide. This amendment is necessary to implement the removal of originator brand data from price disclosure calculations in certain circumstances, as set out in the National Health (Pharmaceutical Benefits) Regulations 2017 (subsection 99ADB(6B) of the National Health Act 1953). By removing originator brand data, the Act aims to potentially increase price disclosure-related price reductions, as originator brands tend to maintain higher prices than other brands. The Act imposes obligations on pharmaceutical companies and the Government to ensure that the PBS operates effectively and efficiently. Pharmaceutical companies must provide the necessary information for determining originator brands, while the Government is responsible for implementing the removal of originator brand data to facilitate price disclosure and reduce out-of-pocket costs for consumers. The Act also requires the Minister or delegate to consider whether the brand was on F1 or CDL when it was first determined as a brand of pharmaceutical item under subsection 85(6) of the Act when deciding whether to determine originator brands (subsection 99ADB(6C)). The determination of originator brands under this Act is not accompanied by specific offences or penalties for breach. However, non-compliance with the requirements of the Act, such as failing to provide the necessary information for determining originator brands, could potentially lead to civil or administrative consequences. For example, pharmaceutical companies may face challenges in obtaining PBS listings or subsidies for their products if they do not comply with the provisions of the Act. Additionally, the Government may take action to ensure compliance with the Act, such as seeking legal advice or pursuing administrative remedies. In summary, the National Health (Originator Brand) Amendment Determination (April Update) 2026 (PB 41 of 2026) amends the National Health (Originator Brand) Determination 2025 to determine originator brands for four pharmaceutical items moving to the F2 formulary on 1 April 2026. This amendment is necessary to implement the removal of originator brand data from price disclosure calculations, potentially leading to increased price disclosure-related price reductions and reduced out-of-pocket costs for consumers. The Act imposes obligations on pharmaceutical companies and the Government to ensure the effective operation of the PBS, and non-compliance with the requirements of the Act could potentially lead to civil or administrative consequences.